Clinical Trial

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-08-01; most recent amendment 2026-05-31.
Trial Details
NCT Number NCT06539182
Lead Sponsor Dizal Pharmaceuticals
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 155 participants
Start Date 2024-04-29
Primary Completion 2027-09 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-02